Katrin S.
- Country
- Germany
- Department
- Klinik fuer Urologie
Research Overview
- Efficacy Comparison of Nivolumab-Ipilimumab Versus Immune Checkpoint Inhibitor-VEGFR TKI Combinations in Untreated Metastatic Renal Cell Carcinoma
- Efficacy of Darolutamide and Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer: A Randomized Controlled Trial
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Saruparib (AZD5305) with Radiotherapy and Androgen Deprivation Therapy in BRCAm High-Risk Prostate Cancer
Data & Insights
Has run more than one trial at 66 of 233 partner sites.
Specializations
Urological Oncology
This investigator specializes in treating advanced urological cancers, with particular emphasis on bladder cancer and its various manifestations, including muscle-invasive and metastatic forms.
- Muscle-invasive bladder cancer
- Metastatic urothelial carcinoma
- Advanced prostate cancer
Their work encompasses both locally advanced disease states and metastatic conditions in the urological system.
Immunotherapy Applications
The investigator focuses on innovative immunotherapeutic approaches in urological cancers, including various immune checkpoint inhibitors and their combinations.
- PD-1/PD-L1 pathway targeting
- LAG-3 based treatments
- TIGIT inhibition strategies
Their expertise extends to both monotherapy and combination immunotherapy regimens.
Treatment Approaches
The investigator develops therapeutic strategies for different stages of urological cancers, including adjuvant therapy and maintenance treatment approaches.
- First-line therapy optimization
- Post-surgical treatment strategies
- Biomarker-guided therapy
Their work includes circulating tumor DNA monitoring and personalized treatment selection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.